Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCL004
MIFTS: 41

B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards integrated aliases for B-Cell Non-Hodgkin Lymphoma:

Name: B-Cell Non-Hodgkin Lymphoma 58 29 6
B-Cell Non-Hodgkins Lymphoma 17
B-Cell Nhl 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA171915
Sources

Summaries for B-Cell Non-Hodgkin Lymphoma

About this section
MalaCards based summary : B-Cell Non-Hodgkin Lymphoma, also known as b-cell non-hodgkins lymphoma, is related to mantle cell lymphoma and diffuse large b-cell lymphoma. An important gene associated with B-Cell Non-Hodgkin Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and FoxO signaling pathway. The drugs Iodine and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for B-Cell Non-Hodgkin Lymphoma

About this section

Diseases in the B-Cell Non-Hodgkin Lymphoma family:

T-Cell Non-Hodgkin Lymphoma

Diseases related to B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 mantle cell lymphoma 31.5 MS4A1 BCL6 ATM
2 diffuse large b-cell lymphoma 31.3 TNFSF13B IL10 BCL6
3 lymphoma, non-hodgkin, familial 31.1 TNFSF13B MS4A1 BCL6 ATM
4 lymphoma 30.7 NFKB2 MS4A1 BCL7A BCL6 ATM
5 splenic marginal zone lymphoma 30.4 NFKB2 BCL6
6 cll/sll 30.4 BCL6 ATM
7 b-cell lymphoma 30.4 TNFSF13B NFKB2 MS4A1 BCL6 ATM
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.1 TNFSF13B IL10
9 cutaneous lupus erythematosus 29.8 TNFSF13B IL10
10 leukemia, chronic lymphocytic 2 29.8 MS4A1 ATM
11 myeloma, multiple 29.8 TNFSF13B IL10 BCL6 ATM
12 leukemia, chronic lymphocytic 29.7 TNFSF13B MS4A1 IL10 BCL6 ATM
13 burkitt lymphoma 29.4 TNFSF13B MS4A1 IL10 BCL7A BCL6 ATM
14 common variable immunodeficiency 29.3 TNFSF13B NFKB2 MS4A1 IL10
15 immune deficiency disease 29.1 TNFSF13B IL10 BCL6 ATM
16 aggressive b-cell non-hodgkin lymphoma 11.5
17 indolent b-cell non-hodgkin lymphoma 11.5
18 lymphoma, hodgkin, classic 11.4
19 follicular lymphoma 11.0
20 neutropenia 11.0
21 marginal zone b-cell lymphoma 10.7
22 thrombocytopenia 10.6
23 leukemia 10.6
24 hepatitis c 10.6
25 hepatitis b 10.5
26 hepatitis c virus 10.5
27 leukemia, acute lymphoblastic 10.5
28 hepatitis 10.4
29 cryoglobulinemia 10.4
30 lymphopenia 10.4
31 lymphosarcoma 10.4
32 cryoglobulinemia, familial mixed 10.4
33 hairy cell leukemia 10.4
34 splenomegaly 10.4
35 lymphoma, mucosa-associated lymphoid type 10.3
36 myelodysplastic syndrome 10.3
37 exanthem 10.3
38 lymphoplasmacytic lymphoma 10.3
39 primary mediastinal b-cell lymphoma 10.3
40 b-lymphoblastic leukemia/lymphoma 10.3
41 cholecystitis 10.3
42 agammaglobulinemia 10.3
43 pneumonia 10.3
44 peripheral nervous system disease 10.3
45 severe combined immunodeficiency 10.3
46 vasculitis 10.3
47 neuropathy 10.3
48 autoimmune disease 10.2
49 hypophosphatemia 10.2
50 paroxysmal nocturnal hemoglobinuria 10.2

Graphical network of the top 20 diseases related to B-Cell Non-Hodgkin Lymphoma:



Diseases related to B-Cell Non-Hodgkin Lymphoma
Sources

Symptoms & Phenotypes for B-Cell Non-Hodgkin Lymphoma

About this section

GenomeRNAi Phenotypes related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.23 IL10 LCP1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.23 ATM IL10 LCP1 NFKB2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.23 ATM LCP1

MGI Mouse Phenotypes related to B-Cell Non-Hodgkin Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 ATM BCL6 IL10 LCP1 MS4A1 NFKB2
2 immune system MP:0005387 9.17 ATM BCL6 IL10 LCP1 MS4A1 NFKB2
Sources

Drugs & Therapeutics for B-Cell Non-Hodgkin Lymphoma

About this section

Drugs for B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Carmustine Approved, Investigational Phase 3 154-93-8 2578
3
Melphalan Approved Phase 3 148-82-3 4053 460612
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Pixantrone Approved, Investigational Phase 3 144510-96-3
6
Daunorubicin Approved Phase 3 20830-81-3 30323
7
Mercaptopurine Approved Phase 3 50-44-2 667490
8
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
10
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
12
Idarubicin Approved Phase 3 58957-92-9 42890
13
rituximab Approved Phase 3 174722-31-7 10201696
14
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Ifosfamide Approved Phase 3 3778-73-2 3690
21
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
22
Mesna Approved, Investigational Phase 3 3375-50-6 598
23
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
24
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
26
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
27
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
28
Lenograstim Approved, Investigational Phase 3 135968-09-1
29
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
30
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
31
ofatumumab Approved Phase 3 679818-59-8 6918251
32
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
33
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
35
Epratuzumab Investigational Phase 3 205923-57-5
36
Cadexomer iodine Experimental Phase 3 94820-09-4
37
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
38
Molgramostim Investigational Phase 3 99283-10-0
39 Vitamin B9 Phase 3
40 Vitamin B Complex Phase 3
41 Folate Phase 3
42 Neuroprotective Agents Phase 3
43 Iodine-131 anti-B1 antibody Phase 3
44
asparaginase Phase 3
45 Folic Acid Antagonists Phase 3
46 Dermatologic Agents Phase 3
47 Antineoplastic Agents, Immunological Phase 3
48 Tubulin Modulators Phase 3
49 Antimitotic Agents Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show top 50) (show all 310)
# Name Status NCT ID Phase Drugs
1 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
2 A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma Completed NCT02910063 Phase 2, Phase 3 Blinatumomab
3 Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL Completed NCT02787239 Phase 3 HLX01;Rituximab;CHOP
4 A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta®, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia Completed NCT02044276 Phase 3 lipegfilgrastim;pegfilgrastim
5 Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma Completed NCT00168740 Phase 3 rituximab
6 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) Completed NCT02747043 Phase 3
7 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
8 A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) Completed NCT00012051 Phase 3 carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate
9 Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+ Completed NCT01285765 Phase 3 RCHOP21
10 Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma Completed NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
11 Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab Completed NCT00064116 Phase 3 CHOP regimen
12 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
13 A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma Completed NCT00312845 Phase 3 Bortezomib + Rituximab;Rituximab
14 The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non Hodgkin's Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab Completed NCT03211065 Phase 2, Phase 3 20% subcutaneous immunoglobulin
15 Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China Recruiting NCT02405676 Phase 2, Phase 3 Prednisone,Vincristine, Cyclophosphamide;Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone;Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone;Rituximab
16 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
17 B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Recruiting NCT03206671 Phase 3 Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine
18 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
19 A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Recruiting NCT03575351 Phase 3 Standard of Care
20 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Active, not recruiting NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
21 A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Active, not recruiting NCT02703272 Phase 3 Ibrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide;Vincristine;Idarubicin;Dexamethasone
22 A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3 Active, not recruiting NCT02367040 Phase 3 Copanlisib (BAY 80-6946);Placebo;Rituximab
23 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Terminated NCT01200589 Phase 3
24 An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgkin's Lymphoma Terminated NCT00562965 Phase 3 inotuzumab ozogamicin;rituximab;rituximab;cyclophosphamide;vincristine;prednisone/prednisolone;mitoxantrone;fludarabine;dexamethasone
25 Randomized Open Label of Ofatumumab and Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Terminated NCT01077518 Phase 3 Ofatumumab;Bendamustine infusion;Ofatumumab and Bendamustine infusions (Arm A);Bendamustine infusion (Arm B)
26 A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT Terminated NCT00006708 Phase 3 carboplatin;etoposide;ifosfamide
27 Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma Terminated NCT00089115 Phase 3
28 A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab Terminated NCT01289223 Phase 3 Bendamustine IV
29 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
30 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
31 A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma Unknown status NCT02456207 Phase 2 SCT400;Rituximab
32 Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Unknown status NCT03105596 Phase 2 Chidamide plus DICE Regimen
33 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life Unknown status NCT00911183 Phase 2 cyclophosphamide;liposome-encapsulated doxorubicin citrate;prednisone;vincristine sulfate
34 Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
35 A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00042913 Phase 2
36 A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy Unknown status NCT00026429 Phase 2
37 Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP Unknown status NCT00022932 Phase 2 Iodine-131 Anti-B1 Antibody
38 Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00006669 Phase 2 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
39 A Phase II, Open-Label, Randomized, Multicenter Trial To Evaluate The Preliminary Safety And Efficacy of Hu1D10 In Patients With Relapsed Or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (Including Follicular, Small Lymphocytic And Marginal Zone/MALT) Unknown status NCT00014664 Phase 2
40 Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial Unknown status NCT01786018 Phase 2 Thiotepa;Busulfan;Fludarabin;Immunosuppression;Cyclosporine;Methotrexate;ATG
41 Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma: a Phase II Multicenter Study of the Fondazione Italiana Linfomi (FIL) Unknown status NCT01990144 Phase 2 Bendamustine+Rituximab
42 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
43 Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status Unknown status NCT00333008 Phase 2 Doxil;Cyclophosphamide;Vincristine;Prednisone;Rituximab;Pegfilgrastim
44 A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma Completed NCT00989586 Phase 1, Phase 2
45 Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma Completed NCT00764517 Phase 2 Cladribine;Vorinostat
46 A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies Completed NCT01921387 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan
47 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
48 Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL) Completed NCT02141451 Phase 1, Phase 2 Rituximab;INCB7839
49 A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma Completed NCT02584920 Phase 1, Phase 2 HLX01;Rituximab
50 Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label). Completed NCT01718691 Phase 2 SyB L-0501;rituximab

Search NIH Clinical Center for B-Cell Non-Hodgkin Lymphoma

Sources

Genetic Tests for B-Cell Non-Hodgkin Lymphoma

About this section

Genetic tests related to B-Cell Non-Hodgkin Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Non-Hodgkin Lymphoma 29
Sources

Anatomical Context for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards organs/tissues related to B-Cell Non-Hodgkin Lymphoma:

40
T Cells, B Cells, Bone Marrow, Pituitary, Myeloid, Eye, Prostate
Sources

Publications for B-Cell Non-Hodgkin Lymphoma

About this section

Articles related to B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 1356)
# Title Authors PMID Year
1
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. 6
9288106 1997
2
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. 61
32944800 2021
3
Clinical Utility of Radiologic Disease Reassessment in the Management of Pediatric B-Cell Non-Hodgkin Lymphoma. 61
32218099 2021
4
Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. 61
33792219 2021
5
Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein-Barr virus-positive follicular lymphoma. 61
33387297 2021
6
What lies beneath: Cutaneous involvement of mantle cell lymphoma underlying an insect-bite-like reaction. 61
32776338 2021
7
Neurolymphomatosis of the median nerve, optic nerve, L4 spinal nerve root and cauda equina in patients with B-cell malignancies: a case series. 61
33766128 2021
8
Primary Burkitt lymphoma of the thyroid gland in a 28-year-old female. 61
33749816 2021
9
Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization. 61
33799222 2021
10
Optimal panel of immunohistochemistry for the diagnosis of B-cell non-Hodgkin lymphoma using bone marrow biopsy: a tertiary care center study. 61
33504685 2021
11
Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. 61
33635332 2021
12
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. 61
33146052 2021
13
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis. 61
33406914 2021
14
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma. 61
33750069 2021
15
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. 61
33739857 2021
16
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 61
32474843 2021
17
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. 61
32578153 2021
18
The treatment of Burkitt lymphoma in adults. 61
33171490 2021
19
Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature. 61
33643507 2021
20
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. 61
33632155 2021
21
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. 61
32880915 2021
22
Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. 61
33448720 2021
23
Small Intestine Posttransplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report. 61
33441059 2021
24
A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and Literature Review. 61
33679144 2021
25
Germline variants of DNA repair genes in early onset mantle cell lymphoma. 61
33191405 2021
26
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. 61
33029633 2021
27
Pancreatic Non-Hodgkin Lymphoma, a rare cause for obstructive jaundice. A Case reports. 61
33401192 2021
28
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. 61
32980545 2021
29
Outpatient fractionated ICE protocol in relapsed/refractory lymphomas: Efficacy and safety. 61
33470173 2021
30
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. 61
33451977 2021
31
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma. 61
33688197 2021
32
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. 61
33186784 2021
33
Erythrocyte levels of cadmium and lead and risk of B-cell non-Hodgkin lymphoma and multiple myeloma. 61
32506449 2020
34
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. 61
33353234 2020
35
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. 61
32856068 2020
36
Expression and role of MIG/CXCR3 axis in mantle cell lymphoma. 61
33197439 2020
37
Co-occurrence of EBV-positive classic Hodgkin lymphoma and B-cell lymphomas of different clonal origins: A case report and literature review. 61
32881147 2020
38
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. 61
32451774 2020
39
Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. 61
33211842 2020
40
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. 61
33232481 2020
41
Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. 61
33187810 2020
42
Primary cutaneous follicle center lymphoma of the breast: Management of an exceedingly rare malignancy. 61
33139988 2020
43
[Experts consensus on current management of children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma]. 61
32987456 2020
44
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 61
32172489 2020
45
[Aggressive mature B-cell non-Hodgkin lymphoma in children and adolescents: curable tumor]. 61
32987455 2020
46
Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database. 61
32599988 2020
47
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. 61
33020647 2020
48
miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. 61
32888820 2020
49
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. 61
33086644 2020
50
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. 61
32856140 2020
Sources

Variations for B-Cell Non-Hodgkin Lymphoma

About this section

ClinVar genetic disease variations for B-Cell Non-Hodgkin Lymphoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ATM NM_000051.3(ATM):c.3118A>G (p.Met1040Val) SNV Pathogenic 3027 rs3092857 GRCh37: 11:108143299-108143299
GRCh38: 11:108272572-108272572
Sources

Expression for B-Cell Non-Hodgkin Lymphoma

About this section
Search GEO for disease gene expression data for B-Cell Non-Hodgkin Lymphoma.
Sources

Pathways for B-Cell Non-Hodgkin Lymphoma

About this section

Pathways related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
RANK Signaling in Osteoclasts 63
Show member pathways
 12.19 TNFSF13B NFKB2 IL10
2
FoxO signaling pathway 36
Show member pathways
 11.63 IL10 BCL6 ATM
3
NF-kappaB Signaling 4
11.54 TNFSF13B NFKB2 LCP1 IL10 BCL6
4
DNA Damage Response (only ATM dependent) 1
11.49 NFKB2 BCL6 ATM
5
Dendritic Cells Developmental Lineage Pathway 64
11.35 MS4A1 IL10
6
NF-kappa B signaling pathway 36
11.35 TNFSF13B NFKB2 ATM
7
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.32 TNFSF13B NFKB2
8
IL4-mediated signaling events 1
11.2 IL10 BCL6
9
DNA damage_ATM/ATR regulation of G1/S checkpoint 23
11.01 NFKB2 ATM
10
IgA-Producing B Cells in the Intestine 64
10.95 TNFSF13B IL10 BCL6
Sources

GO Terms for B-Cell Non-Hodgkin Lymphoma

About this section

Biological processes related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-12-mediated signaling pathway GO:0035722 9.4 LCP1 IL10
2 positive regulation of B cell proliferation GO:0030890 9.37 TNFSF13B BCL6
3 B cell proliferation GO:0042100 9.32 MS4A1 IL10
4 negative regulation of B cell proliferation GO:0030889 9.26 IL10 ATM
5 germinal center formation GO:0002467 9.16 NFKB2 BCL6
6 B cell differentiation GO:0030183 9.13 MS4A1 IL10 BCL6
7 type 2 immune response GO:0042092 8.62 IL10 BCL6
Sources

Sources for B-Cell Non-Hodgkin Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....